drugset / Trial / NCT03596723

KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children

NCT03596723

Phase 3 Terminated 2 enrolled Kala Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children. Approximately half the participants will receive KPI-121 1% eye drops and the other half will receive prednisolone acetate.

Timeline

Start
2018-07-03
Primary completion
2018-09-28
Completion
2018-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Loteprednol Etabonate Other / unclassified 1 % Other
Comparator Prednisolone Other / unclassified 1 % Other

Indications

No indication recorded.